A double-blind split-face randomized controlled trial of the efficacy of 2% Curcuma aeruginosa Roxb. extract-containing cream compared with 2% ketoconazole cream in facial seborrheic dermatitis

Phase 3

Recruiting

• Conditions: facial seborrheic dermatitis; facial seborrheic dermatitis, 2% Curcuma aeruginosa, 2% Ketoconazole

• Registration Number: TCTR20210416002
• Lead Sponsor: Research Administration Section, Faculty of Medicine, Thammasat University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-16
• Study Completion: 2021-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

facial seborrheic dermatitis

Exclusion Criteria

1. Subjects with any untreated or uncontrolled dermatitis on the face, 2. severe co-morbidity, 3. suspected allergy to any study medication, 4. pregnant and lactating women, 5. Subjects who used topical agents(except bland emollients) on the face < 2 weeks before study was initiated, 6. Subjects who had used systemic antifungal agents for > 1 month

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
severity of facial seborrheic dermatitis at 4 weeks scoring index

Secondary Outcome Measures

Name	Time	Method
skin hydration, sebum week 2, 4 corneometer, sebumeter